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Abstract
Background: Several studies have demonstrated that sites of chronic inflammation are often associated with the
establishment and growth of various malignancies. A common inflammatory condition in humans is autoimmune
arthritis (AA). Although AA and cancer are different diseases, many of the underlying processes that contribute to
the disorders of the joints and connective tissue that characterize AA also affect cancer progression and metastasis.
Systemically, AA can lead to cellular infiltration and inflammation of the lungs. Several studies have reported
statistically significant risk ratios between AA and breast cancer. Despite this knowledge being available, there has
been minimal research linking breast cancer, arthritis, and metastasis associated with breast cancer. Notably both
diseases are extremely prevalent in older post-menopausal women.
Methods: To establish the novel link between arthritis induced inflammation and secondary metastasis associated
with breast cancer, PyV MT mice that spontaneously develop mammary gland carcinoma were injected with Type
II collagen (CII) to induce arthritis at 9 and 18 weeks of age for pre-metastatic and metastatic condition. The sites
of secondary metastasis and the associated inflammatory microenvironment were evaluated.
Results: A significant increase in breast cancer-associated secondary metastasis to the lungs and bones was
observed in the arthritic versus the non-arthritic PyV MT mice along with an increase in primary tumor burden. We
report significant increases in the levels of interstitial cellular infiltrates and pro-inflammatory cytokines such as
interleukin-17 (IL-17), interleukin-6 (IL-6), Pro- Matrix metallopeptidase 9 (Pro-MMP9), insulin like growth factor-II (GF-
II) and macrophage colony stimulating factor (M-CSF) in the arthritic lung and bone milieu as well as in the
circulation. These pro-inflammatory cytokines along with the inflammatory microenvironment may be the
underlying factors facilitating tumor progression and metastasis in arthritic PyV MT mice. This was further
substantiated by treatment with celecoxib, an anti-inflammatory drug + aIL-17 antibody that significantly reduced
the secondary metastasis to lung and bone.
Conclusions: The data generated not only reveal the underlying mechanism of high susceptibility to bone and
lung metastasis in an arthritic condition but our combination therapies may lead to treatment modalities that
will be capable of reducing tumor burden, and preventing relapse and metastasis in arthritic patients with
breast cancer.
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While advances have been made in breast cancer thera-
pies, metastatic breast cancer remains an incurable dis-
ease, and thus the prevention of metastases must be a
priority. The preference of breast cancer cells to grow in
t h eb o n ea n dl u n gi su n d e r s c o r e db yt h ef a c tt h a t6 5 -
75% of patients with advanced disease develop metasta-
sis in these organs [1]. We hypothesize that the pro-
inflammatory microenvironment within the bone and
lung caused by certain inflammatory conditions may
partly account for the high prevalence of secondary
metastasis to those organs.
One such common inflammatory condition in humans
is autoimmune arthritis (AA) which results in inflamma-
tion and deformity of the joints. Other systemic effects
associated with arthritis include increased cellular infil-
tration and inflammation of the lungs [2]. Although AA
does not increase the risk for BC, several studies have
reported that compared to cancer patients without rheu-
matoid arthritis (RA), those with RA have poor prog-
nosis and higher mortality. Specifically, patients with
non-Hodgkin’s lymphoma, skin cancer, and BC have sig-
nificantly lower survival if they suffer from RA com-
pared to their non-arthritic counterparts [3-8].
Despite this knowledge available for a decade, it has
not been fully studied in bones and lungs, the sites of
chronic inflammation associated with AA, creates a
milieu that attracts tumor cells to home and grow in
the inflamed organs which are frequent sites of breast
cancer metastasis [8]. There has been minimal research
investigating the link between breast cancer-associated
metastasis and arthritis even though both diseases share
several common molecular pathways of pathogenesis
and both diseases are highly prevalent in post menopau-
sal women.
We have recently shown that the incidence of breast
cancer-associated bone and lung metastasis was signifi-
cantly higher in mice that develop spontaneous arthritis
[9]. This was the first study that undoubtedly established
a correlation between the pro-inflammatory microenvir-
onment in bones and lungs during AA and the homing
of circulating tumor cells in these sites of inflammation.
Data from these studies were further substantiated in a
clinically relevant model of spontaneous metastatic
mammary carcinoma induced to develop arthritis.
Hence, this study is a sequel of our previous study and
our data corroborates a novel link between arthritis
induced inflammation and secondary metastasis asso-
ciated with breast cancer.
The model of spontaneous metastatic mammary gland
tumors known as the MMTV-PyV MT mice carry the
polyoma virus middle T-antigen driven by the mouse
mammary-tumor virus promoter [10-12]. This oncogene
is active throughout all stages of mammary gland devel-
opment, resulting in widespread transformation and
production of multifocal mammary adenocarcinomas
with ~30-40% of the mice exhibiting lung metastasis by
18-26 weeks of age [10-13]. The PyV MT mice were
induced to develop arthritis by administration of Type II
Collagen (CII) at two time points: when the mice were 9
or 18 weeks of age designated pre-metastatic or meta-
static stage respectively. The collagen-induced arthritis
(CIA) model has been the most widely accepted model
for inducing AA in mice. CIA is elicited in mice by
immunization with CII emulsified in complete Freund’s
adjuvant (CFA). The ensuing pathogenesis shares several
pathological features with rheumatoid arthritis (RA),
including synovial hyperplasia, mononuclear cell infiltra-
tion, and cartilage degradation and the mechanism by
which arthritis is induced by collagen injection in these
mice is already established [14,15].
Data clearly demonstrates a significant increase in
bone and lung metastasis and decreased survival in
the arthritic versus the non-arthritic PyV MT mice. In
a d d i t i o n ,w eh a v ei d e n t i f i e ds o m eo ft h ek e yp r o i n -
flammatory factors in the arthritic lung and bone
microenvironment and also in circulation that may
contribute to the increased incidence of secondary
metastasis. Further, we determined that blocking the
COX-2/PGE2 and IL-17 pathways significantly
reduced the formation of secondary metastasis in the
PyV MT mice.
This study is of high importance with vital clinical
implications, especially in the prevention of metastasis,
in designing combination drug regimens, and as a diag-
nostic risk-assessment tool in patients with arthritis and
breast cancer.
Methods
Mice
PyV MT oncogenic mice were originally a gift from Dr.
W. J. Muller (McGill University, Toronto, Canada) [10].
The PyV MT mice that we have used are congenic on
the C57Bl/6 background and have been used in several
of our prior publications [13,16-19]. PCR was used to
routinely identify the PyV MT oncogene. PCR was car-
ried out as described previously [13]. Amplification of
PyV MT gene results in a 480-bp fragment.
All mice were bred and maintained in specific patho-
gen-free conditions in the Mayo Clinic Scottsdale Nata-
lie Schafer Transgenic Animal Facility and UNCC
Animal Facility. All experimental procedures were con-
ducted according to Institutional Animal Care and Use
Committee guidelines. All protocols were approved by
t h eM a y oC l i n i ca n dU N C CI n t e r n a lA n i m a lC a r e
Review Committee.
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The PyV MT mice with spontaneous breast cancer were
injected with 50 μls of 2 mg/ml CII (MD Biosciences,
St. Paul, MN, USA) in CFA (Difco laboratories, Michi-
gan, USA) intradermally ~1.5 cms distal from base of
tail at two time points, at 9 weeks of age when the pri-
mary tumors are undetectable and at 18 weeks of age
when the primary tumors are large enough and metasta-
sis is expected to occur [10,11]. Fifty-sixty percent of
mice develop arthritis within 15-30 days post collagen
injection and the mechanism is established[14].
Generation of PyV MT cells
To generate the PyV MT cell line, the tumors were dis-
sociated in collagenase IV (1 mg/ml)(Worthington Bio-
chemical Corporation, 730 Vassar Ave, NJ 08701) at 37°
C for 30 mins. Then the tumors were meshed, cells
counted and ~3 × 10
6 cells were plated in C-DMEM.
Post 24 hours cells were replenished with fresh media.
Measurement of PGE2 levels in the serum
PGE2 levels in the serum were determined as previously
reported using a specific ELISA kit for PGE2 metabolite
(PGEM) (13, 14-dihydro-15-keto-PGA2) (Cayman Che-
micals, Ann Arbor, MI, USA) [20]. Manufacturer’s
recommended protocols were followed. Serum was
diluted appropriately to ensure that readings were
within the limits of accurate detection. Results are
expressed as picograms of PGEM/per ml. of serum.
Measurement of cytokines
The RayBio
® Custom Mouse Cytokines Antibody Array
kit was purchased from Ray Biotech (Norcross, GA,
USA) and used according to the manufacturer’s instruc-
tions. To measure the cytokines in the lung and bone
microenvironment, 300 and 100 ug of protein was used
respectively. Chemiluminescence was detected using an
EpiChemi3
® Darkroom imaging system and Lab
Works
® densitometry software (both from UVP Bioima-
ging, Upland, CA, USA). Data was corrected for back-
ground signal and normalized to positive controls using
RayBio
® Analysis Tool software as published (UVP Bioi-
maging, Upland, CA, USA).
Invasion Assays
PyV MT cells were serum-starved for 24 hrs prior to
plating for the invasion assay. Cells in serum free media
(50,000 cells) were plated over transwell inserts (BD
Biosciences, San Jose, CA), pre-coated with reduced
growth factor matrigel, and were permitted to invade
towards lung lysate (300 ug protein) and bone lysate
(100 ug protein) contained in the bottom chamber for
24 hours. Percent invasion was calculated as absorbance
of samples/absorbance of controls × 100 [21].
Histology
Lungs and tumor sections were formalin fixed in 10%
neutral-buffered formalin (pH 6.8-7.2) for a minimum of
24 hours. Paraffin embedded blocks was prepared by the
Histology Core at The Mayo Clinic and 4-micron thick
sections were cut for hematoxylin eosin (H&E) staining
and for immuno-staining. Bones were decalcified using
Cal-Rite (Richard Allan Scientific, Kalamazoo, MI), a for-
mic acid decalcification agent prior to IHC. For VEGF,
Pancytokeratin, and PCNA staining, sections were sub-
jected to antigen retrieval using the DAKO Target Retrie-
val agent (Dako North America, Carpentaria, CA, USA).
Primary antibodies to VEGF, PCNA, and pancytokeratin
were purchased from Santa Cruz Biotechnologies, Santa
Cruz, CA, USA and BD Biosciences, CA, USA). To deter-
mine macrophage infiltration, F4/80 antibody was pur-
chased from Abcam, Cambridge, MA, USA.
Corresponding secondary antibodies were purchased
from DAKO. For all slides, 3,3” -Diaminobenzidine (Vec-
tor laboratories, Burlington, CA, USA) was used as the
chromogen and hematoxylin was used as counterstain.
For neutrophil staining, a standard Naphthol AS-D
Chloroacetate Esterase staining using a kit from Sigma
was used. (Sigma, St Louis, MO, USA; Cat: # 91C-1Kit)
was used. Masson trichome staining on bone was used to
determine levels of osteoclasts. All slides were examined
under light microscopy and pictures taken at magnifica-
tions indicated in the Figure legend.
Western Blots and Antibodies
Equal quantities of tumor lysates were loaded on SDS-
PAGE gels. COX-2 and b-actin antibodies were purchased
from Santa Cruz Biotechnology, Santa Cruz, CA and were
used according to manufacturer’s recommendations.
Study design for the IL-17 + celecoxib treatment
To test the efficacy of anti-IL-17 antibody treatment on
breast cancer-associated metastasis, PyV MT mice were
injected with 50 μls of 2 mg/ml CII in CFA at 12 wks.
Post 3-weeks of collagen injection, four i.p injections of
5 μg/ml of anti-IL17 antibody (BD Pharmingen, San
Diego, CA) once every two weeks was administered.
Celecoxib (20 mg/kg in 100 μl 10% DMSO) was gavaged
[22] starting at the same time as the anti-IL-17 antibody
but was given daily until sacrifice except for the week-
ends. One week after the last injection, mice were sacri-
ficed. Controls included PyV MT mice induced with
arthritis and injected with 5 μg/ml rat immunoglobulin
(Ig) G1 control antibody (BD Pharmingen, San Diego,
CA) in 100 μl PBS.
Image Acquisition and Analysis
Bright field images were captured from immunostains of
the mouse tissue using an Olympus microscope
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with magnifications (referred in Figure Legend) using
the DP70 controller, processor and analysis software.
Red-green-blue (RGB)-filtered grayscale values from
images from microscopic slides of mouse tissue, stained
with DAB, hematoxylin or both were analyzed using the
Image-Pro Plus and NIH Image processing and analyz-
ing program [22]. A simple translation algorithm using
the RGB information was developed, providing the
option for separation of DAB only- and double-stained
areas from hematoxylin only-stained areas by means of
subject specific thresholding, based on the correlations
between the R-G- and B-filtered grayscale values. A
good separation of DAB- and double-stained pixels from
hematoxylin-stained pixels was achieved. Significant dif-
ferences in relative areas stained and mean specific
intensity for the stains between control and treatment
groups in mouse tissue were tabulated. N = 3 mice and
5 fields are provided.
The densitometric analyses of immunoblots were per-
formed using NIH Image (obtained from the NIH Web
site: http://rsb.info.nih.gov/nih-image). Results are pre-
sented as mean values of arbitrary densitometric units
corrected for background intensity and normalized to
the expression of b-actin, or as fold increase over levels
in unstimulated cells.
X-Ray imaging
The Pix array 100 x-ray machine was used for bone
imaging. The Pix array 100 (Bi Optic Inc, Santa Clara,
CA, USA) is a commercially available x-ray machine
that is designed for animal x-ray[23]. The analysis was
conducted in Carolinas Medical Center within the
Department of Orthopedic Surgery.
Statistical analysis
Data were analyzed using GraphPad software (GraphPad
Prism version 4.00 for Windows; GraphPad Software,
San Diego, CA, http://www.graphpad.com). Results
expressed as mean ± SEM and are representative of
greater than or equal to three separate experiments.
Comparison of groups were performed using one-way
or two-way ANOVA followed by the Bonferroni post-
test for multiple comparisons (*p < 0.05, **p < 0.01, ***p
<0 . 0 0 1 ) .S t u d e n t ’s t-test was used for comparing the
level of significance between the experimental groups.
Results
Decreased survival in arthritic versus non-arthritic PyV MT
mice
Survival was assessed in PyV MT mice that were
induced to develop autoimmune arthritis (AA) with col-
lagen II injection at week 9 week of age. The PyV MT
mice develop hyperplasia when the mice hit puberty
around 6-8 weeks of age followed by carcinoma-in-situ
and palpable mammary gland tumors by 12-14 weeks of
age leading to invasive adenocarcinoma by 18-24 week
of age. Thus, we were able to study the effect of arthritis
on survival when AA was induced at the pre- metastatic
stages (at 9 weeks of age). This model is clinically rele-
vant, as tumors arise in an appropriate microenviron-
ment, in the context of a viable immune system, and are
phenotypcially similar to human breast tumors. The sur-
vival of the PyV MT mice was significantly diminished
with collagen-induced arthritis where all arthritic mice
had to be euthanized by 149 days (~ 21 weeks) due to
high tumor burden, ulceration of tumor, sluggish
motion, hunched back and interferences with normal
ambulation compared to 170+days (~24-25 weeks) for
PyV MT mice without arthritis (P < 0.001)(Figure 1A).
Remodeling of the primary mammary gland tumor in
arthritic PyV MT mice
PyV MT mice were induced to develop autoimmune
arthritis with collagen II injections at week 9 and week
18 of age (pre and post metastatic stage). We questioned
if the primary tumor itself was affected by the arthritic
milieu. The primary tumor burden was significantly
increased in the PyV MT mice with arthritis compared
to PyV MT mice without arthritis (P < 0.01, n = 10-13
mice) (Figure 1B) regardless of whether arthritis was
induced at pre or post-metastatic stage. Higher tumor
burden correlated with increased cellular infiltration
within the tumor microenvironment which was deter-
mined by quantifying the areas of infiltration in the
H&E stained tumor sections (Figure 2A-F).
Integrated density was used to quantify the levels of
infiltrating cells. Quantification was based on 5 fields
with n = 3 tumor sections per experimental group and
presented in Table 1. Further, we show increased
macrophage infiltration within the PyV MT tumors of
arthritic versus non-arthritic mice indicated by F4/80
staining (Figure 2G-L). The number of F4/80 positive
cells have been counted in 5 fields in n = 3 tumor sec-
tions from each experimental group and results docu-
mented in Table 2. This was accompanied by increased
levels of proliferating cell nuclear antigen (PCNA) stain-
ing (Figure 3A-C) within the tumor implying higher
proliferation in the arthritic versus the non-arthritic
tumors. Table 3 shows the number of PCNA-positive
cells in 5 sections in n = 3 tumors from each experi-
mental group. Since cyclooxygenase-2 (COX-2) and vas-
cular endothelial growth factor (VEGF) are hallmarks of
inflammation, angiogenesis, and metastasis, we investi-
gated the expression of COX-2 and VEGF in the tumors
of our experimental mice. Western blotting was used to
determine COX-2 levels and IHC used to determine
VEGF levels. Significant increases in VEGF and COX-2
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arthritic versus the non-arthritis PyV MT mice (Figure
3D-F and Figure 3G). IHC and Western blots were
quantified and results reported in Tables 4 and 5. Data
suggests that the induction of AA in PyV MT mice cre-
ates a pro-inflammatory and angiogenic microenviron-
ment in the primary tumor, further promoting tumor
progression. All IHC staining were quantified using the
Image-Pro Plus and NIH Image processing and analysis
programs.
Significant increase in osteolytic metastatic lesions in the
arthritic PyV MT versus non-arthritic PyV MT mice
We observed that 50% of arthritic PyV MT mice devel-
oped bone metastasis while none of the non-arthritic PyV
MT mice showed bone metastasis (Figure 4). Bones from
n = 8 mice were analyzed by x-ray imaging for osteolytic
lesions. Representative images from these groups are
shown in Figure 5A-F. Clear osteolytic lesions were
evident in the femur of the arthritic but not the non-
arthritic PyV MT bones (as indicated by the arrow). The
control C57BL/6 mice induced with arthritis did not show
any lesions which confirms that the osteolytic lesions are
driven by the primary mammary gland tumors.
To further confirm epithelial cell lesions, the bone
sections were stained with pancytokeratin and results
are shown in Figure 5G-I. Clear lesions are detected in
the arthritic PyV MT bones but not in the non-arthritic
PyV MT bones.
Significant increase in lung metastasis in the arthritic PyV
MT mice
We observed >2-fold increase in the incidence of lung
metastasis in the arthritic versus non-arthritic PyV MT
mice (7/10 mice with CII administered at 18 wks, and
9/13 mice with CII injected at 9 wks) compared to the
PyV MT mice with no CII (3/11 mice) (Figure 6). Lung
lesions were visualized under dissecting microscope as
Figure 1 Lower survival coupled with higher tumor burden of the arthritic versus non-arthritic PyV MT mice. A: Significant diminution in the
survival of arthritic versus non-arthritic PyV MT mice. N = 6 mice [*p < 0.01 (CII injected at 9 wks of age)]. B: Significantly higher tumor burden in
arthritic versus non- arthritic PyV MT mice. N = 10 mice. *p < 0.01 (CII injected at 9 or 18 weeks) compared to non-arthritic PyV MT mice.
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Page 5 of 20Figure 2 Increased cellular infiltration within the PyV MT tumors of arthritic versus non-arthritic mice. A-F :H&E staining showing
inflammation in the tumor microenvironment; A and D: PyV MT (Low inflammation); B and E: PyV MT + CII at 9 (severe inflammation); C and F:
PyV MT + CII at 18 wks (severe inflammation). The images of tumor sections were taken at 200× (A-C) and 400× (D-F) magnification from the
same area. Representative of n = 10 mice is shown. G-L: Increased macrophage infiltration within the PyV MT tumors of arthritic versus non-
arthritic mice indicated by F4/80 staining. The images of the macrophage staining were taken at 600× magnification. Representative of n = 3
mice is shown.
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and histology showing clear metastasis (indicated by
arrows) (Figure 7G-L). These results are especially sig-
nificant since it represents true metastasis arising from
the spontaneously occurring primary mammary gland
tumors.
Significant inflammation detected in the bones and lungs
of arthritic PyV MT mice
To decipher why primary tumor cells are attracted to
the arthritic bones, we initially conducted histology of
bone sections from all six experimental groups. Repre-
sentative images of H&E staining are shown in Figure
8A-F for bone sections from C57/BL6, C57BL/6 + CII
at 9 wks, C57BL/6 + CII at 18 wks, PyV MT, PyV MT
+ CII at 9 wks, and PyV MT + CII at 18 wks. Enhanced
inflammation with increased cellular infiltration was
clearly observed in the C57/BL6 bones from arthritic
mice as compared to the non-arthritic C57BL/6 and
PyV MT bones. The severity of inflammation was aug-
mented with arthritic PyV MT bones suggesting that
the metastatic PyV MT tumor may have the potential to
enhance the severity of arthritis (Figure 8A-F). N = 8
mice were evaluated with similar results. The results are
tabulated as integrated density (IntDen) from n = 3
mice in Table 6. Inflammatory signals are known to
induce osteoclast maturation and bone resorption
during CII-induced arthritis. Such phenomena mainly
occur at the interface between proliferating synovium
and bone tissue in arthritis. High cellular infiltration in
the arthritic PyV MT mice was associated with
increased bone destruction as evidenced by the
increased osteoclasts in these mice (Figure 8G-L) as
compared with PyV MT with no CII. Taken together
these data suggest that the metastatic breast cancer cells
may contribute to the vicious cycle of osteolytic
destruction.
To further demonstrate the chemotactic microenvir-
onment in the lungs of arthritic versus non-arthritic
mice, lung histology was examined. Moderate inflamma-
tion was noted in the C57BL/6 mice with arthritis com-
pared to no inflammation in the non-arthritic C57BL/6
lungs. Significantly enhanced inflammation with
increased cellular infiltration was observed in the lungs
of PyV MT mice injected with collagen compared to
PyV MT mice without collagen and compared to con-
trol C57BL/6 mice with collagen (Figure 8M-R). The
pro-inflammatory phenotype in the lung correlated with
the severity and incidence of lung metastasis (Figure 7)
suggesting the critical role of inflammatory cells in pro-
moting metastasis.
In addition, we demonstrate neutrophillic infiltration
in the bones and lungs of arthritic versus non-arthritic
PyV MT mice, another indicator of increased inflamma-
tion in the arthritic organs. Representative images are
shown in Figure 9A-C for bones and Figure 9D-F for
lungs from the arthritic and non-arthritic PyV MT mice.
Enhanced invasion of PyV MT tumor cells towards
arthritic bone and lung lysate
Thus far, our data suggests that the increased cellular
infiltration in the lungs and bones of the arthritic mice
versus the non-arthritic mice may be one of the
Table 1 Quantification of inflammation in the tumors of
arthritic versus non-arthritic PyV MT mice
Quantification in tumor IntDen Inflammation
PyV MT 50.3 ± 19
PyV MT + CII at 9 wks 322 ± 17
PyV MT + CII at 18 wks 337 ± 22
Integrated density (IntDen) from 5 fields per tumor in n = 3 animals from
each experimental group.
Table 2 F4/80 positive cells in the tumors of arthritic versus non-arthritic mice (5 fields from n = 3 mice were counted)
F4/80
positive cells
at 600×
magnification
Field 1 Field 2 Field 3 Field 4 Field 5 Average StdDev
PyV MT 1 1 1 2 0 0 0.8 0.84
PyV MT 2 0 0 4 1 1 1.2 1.64
PyV MT 3 3 1 2 0 0 1.2 1.30
PyV MT + CII at 9 wks 1 23 15 12 4 5 11.8 7.79
PyV MT + CII at 9 wks 2 19 7 10 18 17 14.2 5.36
PyV MT + CII at 9 wks 3 22 16 18 21 16 18.6 2.79
PyV MT + CII at 18 wks 1 23 15 19 14 16 17.4 3.65
PyV MT + CII at 18 wks 2 18 18 12 13 22 16.6 4.10
PyV MT + CII at 18 wks 3 17 23 15 19 17 18.2 3.03
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Page 7 of 20Figure 3 Increased expression of PCNA, VEGF and COX-2 in the arthritic PyV MT tumors. A-C: Higher number of PCNA positive cells in
the tumors of arthritic PyV MT versus non-arthritic PyV MT. D-F: Increased expression of VEGF in the arthritic PyV MT tumors. The images of
tumors were taken at 200× magnification. Brown staining represents positive PCNA and VEGF staining. Representative of n = 10 mice is shown.
G: Western blot analysis of COX-2 expression. b-actin serves as control for equal protein loading.
Table 3 PCNA positive cells in the tumors of arthritic versus non-arthritic mice (5 fields from n = 3 mice were counted)
PCNA positive cells at 400× magnification
Field 1 Field 2 Field 3 Field 4 Field 5 Average StdDev
PyV MT 1 50 30 34 50 55 43.8 11.05
PyV MT 2 27 40 50 25 32 34.8 10.28
PyV MT 3 34 37 48 53 50 44.4 8.38
PyV MT + CII at 9 wks 1 100 87 92 95 84 91.6 6.35
PyV MT + CII at 9 wks 2 105 94 86 96 107 97.6 8.56
PyV MT + CII at 9 wks 3 97 80 78 94 73 84.4 10.50
PyV MT + CII at 18 wks 1 120 80 125 115 85 105 20.92
PyV MT + CII at 18 wks 2 97 112 87 88 94 95.6 10.06
PyV MT + CII at 18 wks 3 89 75 96 74 85 83.8 9.36
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tasis observe in the arthritic mice (Figures 4, 5, 6, 7, 8,
9). To substantiate the chemotactic potential of the
arthritic bone and lung, bone and lung lysates of the
arthritic and non-arthritic mice were used as the che-
motactic factor in an in vitro trans-well matrigel inva-
sion assay with the PyV MT cells (generated from
primary PyV MT tumors) in the top chamber and the
bone and lung lysates in the bottom chamber. Data
clearly shows that the lung and bone microenvironment
was significantly altered in the arthritic mice to become
more chemo-attractant to the PyV MT tumor cells (Fig-
ure 10A and 10B). Statistically significant difference is
provided between PyV MT and PyV MT + CII at 9 and
18 weeks as well as C57Bl/6 and C57Bl/6 + CII at 9 and
18 weeks.
IL-17, IL-6, Pro-MMP9, IGF-II, and M-CSF may be the
underlying factors responsible for the increased
metastasis in the lungs and bones of arthritic mice
To determine which factors in the bone and lung
microenvironment may be responsible for higher inva-
sion, thereby driving the breast cancer cells to become
more metastatic in the arthritic model, we used the
RayBio
® Custom Mouse Cytokines Antibody Array.
The arthritic lungs and bones expressed significantly
higher levels of cytokines and growth factors which
included IL-17, IL-6, Pro-MMP9, IGF-II, and M-CSF
(Figure 10C and 10D). This was regardless of whether
the arthritis was induced at 9 or 18 wks of age sug-
gesting that the arthritic milieu remains stable even at
10-12 weeks post CII injection. The levels of the pro-
inflammatory cytokines were found to be higher in
arthritic C57BL/6 lungs and bones compared to the
non-arthritic C57BL/6.
Thus, we hypothesize that the pro-inflammatory
microenvironment in the arthritic bone and lungs may
boost the recruitment of the PyV MT tumor and that
the PyV MT tumor in turn significantly augments the
levels of the cytokines in these target organs thus creat-
ing a highly conducive microenvironment for the PyV
MT tumors to further proliferate.
High levels of circulating PGE2 coupled with increased
levels of pro-inflammatory cytokines in circulation may
initiate primary tumors to be more metastatic in arthritic
milieu
We also evaluated the circulating levels of pro-inflam-
matory cytokines and chemokines in the sera of the
arthritic versus the non-arthritic mice. These same fac-
tors (IL-17, IL-6, Pro-MMP9, IGF-II, and M-CSF) were
also found to be elevated in the circulation suggesting
their role in possibly initiating the primary tumors to be
more metastatic (Figure 11A). Data is presented as den-
sitometry units.
Lastly, but expectedly, we detected significant increase
in PGE2 levels in the circulation (Figure 11B). Elevated
Table 4 Quantification of VEGF staining in tumors
(Average IntDen from 5 fields per tumor from n = 3 mice
is shown)
Quantification in tumor IntDen
VEGF
PyV MT 424.93 ± 19
PyV MT + CII at 9 wks 2021.8 ± 21
PyV MT + CII at 18 wks 2788.8 ± 28
Table 5 Densitometry analysis of the COX-2 expression in
the tumor using the image J software (data from n = 3
mice is shown)
Groups Densitometry analysis: COX2
PyV MT 1 22.28
PyV MT 2 24.21
PyV MT 3 21.67
PyV MT + CII at 9 wks 1 41.65
PyV MT + CII at 9 wks 2 40.45
PyV MT + CII at 9 wks 3 50.23
PyV MT + CII at 18 wks 1 58.17
PyV MT + CII at 18 wks 2 55.41
PyV MT + CII at 18 wks 3 45.15
Figure 4 Percentage of mice with bone metastasis. Fifty percent
of arthritic PyV MT mice developed bone metastasis compared to
its non-arthritic counterpart with no bone metastasis (n = 10-13
mice).
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Page 9 of 20Figure 5 Metastatic bone lesions accompanied with increased expression of Pancytokeratin in the bones of arthritic PyV MT mice. A-
F: Representative x-ray images of bones. A-D: Bones from C57/BL6 mice injected with CII at 9 and 18 wks and PyV MT mice with no metastatic
lesions; E and F: Bones from PyV MT + CII at 9 wks and 18 wks respectively (shows distinct severe osteolytic bone lesion in distal femur as
indicated by the arrow). N = 8 mice from each group were examined using the x-ray imaging. G-I: Pancytokeratin positive staining observed in
the bones of arthritic PyV MT mice. Brown staining represents positive staining. The images were taken at 400× magnification. Representative of
n = 10 mice is shown.
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Page 10 of 20PGE2 is a hall mark of arthritis and is known to enhance
primary tumor cells to become highly angiogenic and
metastatic.
Treatment with anti-IL-17 and a COX-2 inhibitor
significantly reduced the secondary metastasis in the
arthritic PyV MT mice
The goal of our studies is to find a possible therapy for
arthritis-induced breast cancer metastases. Both IL-17
and COX-2 are reasonable targets as both were up-regu-
lated in the arthritic mice and both are used clinically
for treatment of arthritis. IL-17 is known to also med-
iate proinflammatory effects by stimulating the release
of multiple other cytokines such as IL-6, IL-8, GM-CSF,
TGF-b,T N F - a and G-CSFs from epithelial, endothelial,
and fibroblastic cells. In addition, it is an emerging ther-
apeutic target for cancer metastasis and arthritis [24-26].
High levels of cyclooxygenase 2 (COX-2) is linked to
both AA and breast cancer metastasis [27]. We treated
the arthritic PyV MT mice with a combination of cele-
coxib, a specific COX-2/PGE2 inhibitor, and a neutraliz-
ing antibody against IL-17. Excitingly, the incidence of
secondary metastasis was significantly reduced in the
arthritic PyV MT mice treated with a combination of
celecoxib and a neutralizing antibody against IL-17 (Fig-
ure 12A and 12B). Lysates from metastatic sites in trea-
ted mice were further evaluated for their chemo
attractant properties and were found to be significantly
less attractant than bone and lung lysates from
untreated arthritic PyV MT mice (Figure 12C and 12D).
In fact the level of chemo attractant was as low as the
non-arthritic PyV MT mice suggesting that the anti-IL-
17 antibody and celecoxib reduced the levels of IL-17
and PGE2 which in turn reduced the levels of all other
factors that were up regulated in the arthritic lung and
bone lysates (data not shown).
Discussion
Inflammation is a critical component of tumor progres-
sion and metastasis as well as arthritis [28-31]. Many
processes that occur during arthritis also occur during
tumorigenesis including uncontrollable growth, inflam-
mation, increased vascularity and common cytokines
a n dg r o w t hf a c t o r st h a ta r er e g u l a t e di nb o t h .T h e
tumor microenvironment, which is largely orchestrated
by inflammatory cells, is critical in the neoplastic pro-
cess, fostering proliferation, survival and migration [32].
It is indeed interesting that post-menopausal women
who are usually prone to developing some form of auto-
immune arthritis including osteoarthritis, RA, or inflam-
matory polyarthritis are also the most likely candidates
to develop breast cancer. Thus, it is not unlikely that
the two diseases co-exist in these women. Although
there are several studies implicating inflammation as the
initiator of tumor formation and/or mediator of progres-
sion, there is minimal research on whether prior inflam-
mation at the site of metastasis produces a fertile
ground for primary tumor cells to home and proliferate.
Our study begins to evaluate whether arthritis which
causes inflammation in the bones and lungs enhances
secondary metastasis to those sites. A significant
increase in breast cancer-associated metastasis to the
lungs and bones was observed in the arthritic versus the
non-arthritic PyV MT mice (Figures 4, 5, 6, 7) along
with increase in primary tumor burden (Figure 1). Com-
pared with the non-arthritic C57BL/6, the lungs and
bones of the arthritic C57BL/6 expresses moderate levels
of inflammation even before any tumor challenge sug-
gesting a pro-inflammatory milieu that may be responsi-
ble for attracting the PyV MT metastatic cells to the
lungs and bones as demonstrated in the in vitro invasion
assay (Figure 10A and 10B). Once the PyV MT cells
home to the lungs or bones, the levels of interstitial cel-
lular infiltrates and pro-inflammatory cytokines are
exponentially increased which is characterized by promi-
nent cytokines IL-17, IL-6, Pro-MMP9, IGF-II and M-
CSF (Figure 10C and 10D). The levels of these cytokines
along with PGE2 are also upregulated in the circulation
(Figure 11A and 11B). These pro-inflammatory cyto-
kines along with inflammatory microenvironment can
facilitate tumor cell extravasation and promote metasta-
sis. This is further substantiated when treatment with
celecoxib + aIL-17 antibody significantly reduced the
Figure 6 Percentage of PyV MT mice that developed lung
metastasis. PyV MT mice + CII at 9 and 18 wks had two fold
increase in lung metastasis as compared to PyV MT without CII (n =
10-13 mice).
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Page 11 of 20Figure 7 Images demonstrating clear metastatic lesions in the lungs of arthritic PyV MT mice. A-F: Representative images of lungs
showing metastatic lesions. A-C:C57/BL6 mice, C57/BL6+CII at 9 and 18 wks (no metastatic lesions) D: PyV MT mice(no metastatic lesions); E
and F: PyV MT+ CII at 9 and 18 wks respectively (arrows represent lung lesions); G-L: H&E of the lung sections: The arrows represent metastatic
lesions in PyV MT + CII at 9 and 18 wks (K and L) versus no lesions in control C57/BL6, C57/BL6 + CII at 9 or 18 wks and PyV MT lung (G - J). N
= 10-13 mice from each group were examined with similar results. The images of the H&E sections were taken at 400× magnification.
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Page 12 of 20Figure 8 Histology of bones and lungs, and osteoclast staining of bones of the arthritic versus non-arthritic PyV MT mice. A-F: H&E
staining of sections from the joints. A: C57BL/6 (no inflammation);B :C57BL/6 mice + CII at 9 wks (moderate inflammation); C: C57BL/6 mice +
CII at 18 wks (moderate inflammation); D: control PyV MT mice (no inflammation); E: PyV MT mice + CII at 9 wks (erosion of articular cartilage
and bone with severe inflammation); F: PyV MT mice + CII at 18 wks (severe inflammation in the phalangeal joints); G-L: Masson trichome
staining of bone sections for presence of osteoclasts. G: C57/BL6 mice (no osteoclasts); H: C57BL/6 + CII at 9 wks (few osteoclasts marked with
arrows); I: C57BL/6 mice + CII at 18 wks (few osteoclasts marked with arrows); J: PyV MT mice (no osteoclasts); K: PyV MT mice + CII at 9 wks
(multiple osteoclasts marked with arrows); L: PyV MT mice + CII at 18 wks (multiple osteoclasts marked with arrows). M-R: H&E staining of
sections from the lungs. M: control C57BL/6 (no inflammation); N: C57BL/6+CII at 9 wks(moderate inflammation); O: C57BL/6+CII at 18 wks
(moderate inflammation); P: control PyV MT mice (no inflammation); Q: PyV MT mice + CII at 9 wks (severe inflammation); R: PyV MT mice + CII
at 18 wks (severe inflammation). The H&E images of the joints and lungs were taken at 200× and 400× magnification respectively and the
Masson Trichome bone images taken at 400× magnification. Representative of n = 10 mice is shown.
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Page 13 of 20metastasis to lung and bone (Figure 12). This study
undoubtedly authenticates our previous study [9].
The tumor microenvironment itself is regarded as a
“smoldering” inflammation site in which many cyto-
kines, chemokines, and enzymes mediate the inflamma-
tory process and drive malignant progression [33]. We
observed increased inflammation into the tumor site of
the arthritic PyV MT mice possibly remodeling the
tumor microenvironment (Figure 2). For tumors to
develop in size and amplify metastatic potential, they
must make an “angiogenic switch” through perturbing
the local balance of pro-angiogenic and anti-angiogenic
Table 6 Quantification of inflammation in the bones
(Average IntDen from 5 fields per bone from n = 3 mice
is shown).
Quantification of inflammation in bone
Group IntDen
C57BL/6 0
C57BL/6 + CII at 9 wks 50 ± 38
C57BL/6 + CII at 18 wks 72 ± 12
PyVMT 0.0
PyV MT +CII at 9 wks 232 ± 15
PyV MT +CII at 18 wks 265 ± 20
Figure 9 Increased infiltration of neutrophils in the bones and lungs of arthritic PyV MT mice. A-F: Naphthol AS-D chloroacetate esterase
staining of the bones and lungs for neutrophils. Increased infiltration of neutrophils in bones (A-C) and lungs (D-F) of arthritic PyV MT mice
indicated by arrows. Representative of 10 fields in n = 10 mice is shown. The images of the bones and lungs were taken at 400× and 200×
magnification respectively.
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Page 14 of 20Figure 10 Higher invasion of PyV MT cells towards the bone and lung lysate of the arthritic versus non-arthritic PyV MT mice.U p
regulation of several cytokines in the lung and tumor microenvironment. A and B: Significantly higher invasion index of the PyV MT tumor cells
towards the arthritic bone and lung lysate in an in vitro matrigel invasion assay (* p < 0.05 compared to the non-arthritic PyV MT lung and bone
lysate). C and D: A graphical representation of the up regulated cytokines in the bone and lung lysate (*p < 0.05, **p < 0.01, ***p < 0.001). The
Ray Biotech cytokine array kit was utilized for this experiment. Average of n = 4 mice. The statistical differences between groups are shown with
horizontal bars. We have compared 1) C57Bl/6 with C57Bl/6 + CII at 9 and 18 weeks; and 2) PyV MT with PyV MT + CII at 9 and 18 weeks.
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Page 15 of 20Figure 11 Serum analysis revealed up regulation of various cytokines along with PGE2 which may be the underlying factor
contributing to increased metastasis in arthritic mice. A: A graphical representation of the up regulated cytokines in the bone and lung
lysate (*p < 0.05, **p < 0.01, ***p < 0.001). The Ray Biotech cytokine array kit was utilized for this experiment and average of n = 4 mice. B:
Increased circulating PGE2 in the arthritic versus the non-arthritic PyV MT mice (*p < 0.01 versus PyV MT mice), n = 10 mice per group. A specific
ELISA was used for this experiment. The statistical differences between groups are shown with horizontal bars. We have compared the statistical
differences between 1) C57Bl/6 with C57Bl/6 + CII at 9 and 18 weeks; and 2) PyV MT with PyV MT + CII at 9 and 18 weeks.
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Page 16 of 20Figure 12 Treatment with anti-IL17 antibody and celecoxib significantly reduced secondary metastasis in the arthritic PyV MT mice.
Percent of mice that developed A) bone and B) lung metastasis post treatment. Fifty percent decrease in bone and lung metastasis in mice
treated with the combination therapy. N = 4 mice per group. C and D: Percent of PyV MT cells that invaded through the matrigel in an in vitro
invasion assay with C) bone lysate or D) lung lysate in the bottom chamber. Lysates from lung and bone of treated arthritic PyV MT mice were
significantly less chemotactic than lysates from untreated arthritic PyV MT mice. (* p < 0.05). N = 3 from each group. The statistical differences
between groups are shown with horizontal bars. The statistical differences were compared between 1) C57Bl/6 with C57Bl/6 + CII at 9 and 18
weeks; and 2) PyV MT with PyV MT + CII at 9 and 18 weeks.
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Page 17 of 20factors. Frequently, tumors over express pro-angiogenic
factors, such as PGE2 and VEGF, allowing them to
make this angiogenic switch [34]. We observed
increased VEGF and COX-2 expression in the tumors of
arthritic PyV MT mice compared to non-arthritic
tumors (Figure 3) possibly inducing an “angiogenic
switch” and contributing to invasiveness of the cells.
Cytokines and prostaglandins play an essential role in
the development of arthritis [35]. Several cytokines have
been implicated in the mechanism of synovial cell acti-
v a t i o na n dj o i n td e s t r u c t i o ni nA A[ 3 6 ] .A tt h es a m e
time, cytokines also play an imperative role in cancer
development and progression. In fact, elevated serum
M-CSF predicts reduced survival in metastatic breast
cancer patients [37]. At the same time, the M-CSF pro-
duced by breast cancer cells and surrounding stroma
increases osteoclast formation and maturation and
enhances the expression of stromal RANK ligand, both
of which increase osteolytic bone degradation [38]. M-
CSF also contributes to the pathogenesis of RA through
up regulation of neutrophil gelatinase-associated lipoca-
lin (NGAL) in neutrophils, followed by induction of
transitional endoplasmic reticulum ATPase (TERA),
cathepsin D and transglutaminase 2(TG2) in synovio-
cytes [39]. Pro-MMP9 concentration in sera and joint
fluids of RA patients is reported to be significantly
higher which correlates with our mouse model where
the Pro-MMP9 levels are up regulated in the arthritic
bone, lungs microenvironment as well as in the sera
[40]. It is reported that cathepsin G is up regulated
through tumor stromal interactions and activates Pro-
MMP9, active MMP9 cleaves and releases active TGF-
beta, and active TGF-beta can then promote tumor
growth and enhance osteoclast activation and subse-
quent bone resorption [41]. Over expression of IGF-II is
reported in multiple types of cancer and is proposed as
a potential mechanism for cancer cells to develop resis-
tance to IGF-1R-targeting therapy [42]. IL-17 acts on
osteoblasts by stimulating COX-2-dependent PGE2 and
osteoclast differentiation factor which differentiates
osteoclast progenitors into mature osteoclasts, causing
bone resorption. PGE2 interacts with its eicosanoid
receptors to induce the damage [26]. It is found that
synovial fluids of patients with RA contain high levels of
the cytokines IL-17 and IL-15 [43]. Cytokines play a
crucial role in the regulation of inflammatory events.
Inflammatory disorders such as RA are characterized by
an overproduction of several cytokines including IL-6
[ 4 4 ] .I L - 6o nt h eo t h e rh a n di sa na u t o c r i n ea n dp a r a -
crine growth factor for several cancers, including breast
cancer [45,46] and both IL-17 and IL-6 stimulates can-
cer cell growth and contributes to recurrence and
metastasis in breast cancer [47-49].
Conclusion
The data clearly shows that breast cancer associated
metastasis is increased in arthritic conditions and block-
ing the IL-17 and COX-2 pathways significantly reduces
the development of secondary metastasis in a sponta-
neous model of breast cancer induced to develop
arthritis.
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